14 results on '"Lu, Qiongyu"'
Search Results
2. Single‐cell RNA‐seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML.
- Author
-
Lu, Qiongyu, Qu, Wenqiang, Wen, Yuxin, Ke, Peng, Zhao, Luyao, Wang, Qingyuan, Chen, Suning, and Zeng, Zhao
- Subjects
- *
ACUTE myeloid leukemia , *METABOLOMICS , *RNA sequencing , *HETEROGENEITY , *HEMATOPOIETIC stem cells , *CYTOTOXIC T cells - Abstract
This article explores the metabolic heterogeneity of acute myeloid leukemia (AML) at the single-cell level. The study reveals that AML cells exhibit distinct metabolic features and that metabolic heterogeneity is correlated with cell differentiation and certain genetic alterations. The researchers also found that primitive cell types in both normal bone marrow and AML display higher metabolic heterogeneity. The findings highlight the importance of understanding metabolic heterogeneity for identifying drug-resistant subtypes of cells and improving therapeutic interventions for AML. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
3. Corrigendum to “Sema7A protects against high-fat diet-induced obesity and hepatic steatosis by regulating adipo/lipogenesis” [Mol Metab. 70 (2023) 101698]∗
- Author
-
Lu, Qiongyu, Liu, Ziting, Zhao, Luyao, Xu, Linru, Liu, Chu, Li, Ling, Cao, Yiren, Li, Fengchan, Wu, Lili, Wang, Lei, Chen, Ting, You, Tao, Ren, Lijie, Wang, Guixue, Tang, Chaojun, and Zhu, Li
- Published
- 2023
- Full Text
- View/download PDF
4. Endothelial CCRL2 induced by disturbed flow promotes atherosclerosis via chemerin-dependent β2 integrin activation in monocytes.
- Author
-
Tang, Chaojun, Chen, Guona, Wu, Fan, Cao, Yiren, Yang, Fei, You, Tao, Liu, Chu, Li, Menglu, Hu, Shuhong, Ren, Lijie, Lu, Qiongyu, Deng, Wei, Xu, Ying, Wang, Guixue, Jo, Hanjoong, Zhang, Yonghong, Wu, Yi, Zabel, Brian A, and Zhu, Li
- Subjects
INTEGRINS ,ATHEROSCLEROTIC plaque ,CHEMERIN ,ATHEROSCLEROSIS ,MONOCYTES ,WESTERN diet - Abstract
Aims Chemoattractants and their cognate receptors are essential for leucocyte recruitment during atherogenesis, and atherosclerotic plaques preferentially occur at predilection sites of the arterial wall with disturbed flow (d-flow). In profiling the endothelial expression of atypical chemoattractant receptors (ACKRs), we found that Ackr5 (CCRL2) was up-regulated in an endothelial subpopulation by atherosclerotic stimulation. We therefore investigated the role of CCRL2 and its ligand chemerin in atherosclerosis and the underlying mechanism. Methods and results By analysing scRNA-seq data of the left carotid artery under d-flow and scRNA-seq datasets GSE131776 of ApoE
−/− mice from the Gene Expression Omnibus database, we found that CCRL2 was up-regulated in one subpopulation of endothelial cells in response to d-flow stimulation and atherosclerosis. Using CCRL2−/− ApoE−/− mice, we showed that CCRL2 deficiency protected against plaque formation primarily in the d-flow areas of the aortic arch in ApoE−/− mice fed high-fat diet. Disturbed flow induced the expression of vascular endothelial CCRL2, recruiting chemerin, which caused leucocyte adhesion to the endothelium. Surprisingly, instead of binding to monocytic CMKLR1, chemerin was found to activate β2 integrin, enhancing ERK1/2 phosphorylation and monocyte adhesion. Moreover, chemerin was found to have protein disulfide isomerase-like enzymatic activity, which was responsible for the interaction of chemerin with β2 integrin, as identified by a Di-E-GSSG assay and a proximity ligation assay. For clinical relevance, relatively high serum levels of chemerin were found in patients with acute atherothrombotic stroke compared to healthy individuals. Conclusions Our findings indicate that d-flow-induced CCRL2 promotes atherosclerotic plaque formation via a novel CCRL2-chemerin-β2 integrin axis, providing potential targets for the prevention or therapeutic intervention of atherosclerosis. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
5. Prognostic impact of PRDM16 expression in acute myeloid leukemia with normal cytogenetics.
- Author
-
Xiang, Xin, Lu, Qiongyu, Xu, Xiaoyu, Cai, Ping, Chen, Suning, Pan, Jinlan, and Zeng, Zhao
- Subjects
- *
GENE expression , *ACUTE myeloid leukemia , *CYTOGENETICS , *HEMATOPOIETIC stem cells , *MOLECULAR genetics - Abstract
Cytogenetically normal acute myeloid leukemia (CN-AML) is a heterogeneous disease with variable clinical outcomes. The identification of potential biomarkers to better classify the patients with unfavorable prognoses who may require more aggressive therapies is an emergent demand. PRDM16 is a transcriptional cofactor and histone methyltransferase, playing a critical role in maintaining hematopoietic stem cells, and MLL fusion-induced leukemogenesis. However, the prognostic value of PRDM16 in CN-AML is still unclear. We retrospectively analyzed the PRDM16 expression and its association with gene mutations in CN-AML. Then the prognostic value of PRDM16 and its comparison with WT1 were analyzed. The results showed that about 73.6% of CN-AML patients harbored higher expression of PRDM16 than the healthy controls. Furthermore, CN-AML patients with high PRDM16 expression had a lower survival rate than the low PRDM16 expression group (50.5% vs. 83.3%, p = 0.0339). Interestingly, hemopoietic stem cell transplantation significantly improved the prognosis of CN-AML with high PRDM16 expression but not those with low PRDM16 expression. In terms of molecular genetics, high PRDM16 expression was significantly associated with a lower rate of CEBPA mutation (p = 0.01) and a higher rate of FLT3-ITD and DNMT3A mutation (p = 0.032 and p = 0.004, respectively). In addition, PRDM16 expression was significantly correlated with WT1 expression in CN-AML (r = 0.7, p < 0.001). These data suggested PRDM16 expression could be used to predict the outcome of patients with CN-AML. PRDM16 is significantly associated with FLT3-ITD and DNMT3A mutation and WT1 expression and serves as a potential prognostic biomarker in CN-AML. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Case Report: The Formation of a Truncated PAX5 Transcript in a Case of Ph-Positive Mixed Phenotype Acute Leukemia With dic(7;9)(p11-p13;p13).
- Author
-
Yu, Yan, Zeng, Zhao, Xie, Jundan, Lu, Qiongyu, Cai, Wenzhi, Zhang, Ruixi, Pan, Jinlan, Zhao, Yun, Sun, Aining, Qiu, Huiying, and Chen, Suning
- Subjects
ACUTE leukemia ,PHENOTYPES ,UBIQUITIN-conjugating enzymes ,CHROMOSOMAL translocation ,GENE fusion - Abstract
PAX5 plays a critical role in B-cell precursor development and is involved in various chromosomal translocations that involve the fusion of a portion of PAX5 to at least 49 different partners reported to date. Here, we identified a novel PAX5 fusion transcript in a Ph-positive mixed phenotype acute leukemia case with dic(7;9)(q13;q13), in which a translocation juxtaposes the 5' region of PAX5 and the ubiquitin-conjugating enzyme E2D4 (UBE2D4) to generate a PAX5-UBE2D4 fusion gene. To further explore the general characteristics and function of PAX5-UBE2D4, we cloned the full-length cDNA, which was amplified from the bone marrow of the patient. Interestingly, the fusion was located in the nucleus and negatively affected PAX5 transcription activity. Importantly, the fusion promoted tumor growth in nude mice and the proliferation of NIH3T3 cells in vitro. In conclusion, the fusion resulted in partial oncogenic activity, in contrast to the tumor suppressor activity of wild-type PAX5. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Sema4D correlates with tumour immune infiltration and is a prognostic biomarker in bladder cancer, renal clear cell carcinoma, melanoma and thymoma.
- Author
-
Lu, Qiongyu, Cai, Ping, Yu, Yan, Liu, Ziting, Chen, Guona, and Zeng, Zhao
- Subjects
- *
RENAL cell carcinoma , *BLADDER cancer , *BIOMARKERS , *MELANOMA , *PROGNOSIS - Abstract
Sema4D, a member of the immune semaphorin family, plays crucial roles in the immune regulation, bone resorption and nervous system. It is also involved in angiogenesis and tumour progression. However, systemic studies on the correlation between Sema4D expression and the immune infiltration or clinical outcomes in tumours are still limited. Here, we analysed the landscape of Sema4D expression and its prognostic value in the cancer genome atlas pan-cancer as well as the correlation between Sema4D and immune cell infiltration by Tumour Immune Estimation Resource and Gene Expression Profiling interactive analysis online tools. Results showed that a higher Sema4D expression was significantly correlated with a favourable overall survival in diverse solid tumours including bladder cancer (Hazards Ratio (HR)=0.68, p =.0095), kidney renal clear cell carcinoma (HR = 0.61, p =.0016), melanoma (HR = 0.58, p = 6.6e-05) and thymoma (HR = 0.1, p =.011). Interestingly, Sema4D expression has positive correlation with various tumour infiltrating immune cells and immune cell biomarkers in these tumours. These results suggest that Sema4D could be a prospective biomarker for calculating hazard ratio of tumour patients and their tumour immune infiltration levels. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Serum semaphorin 7A is associated with the risk of acute atherothrombotic stroke.
- Author
-
You, Tao, Zhu, Zhengbao, Zheng, Xiaowei, Zeng, Nimei, Hu, Shuhong, Liu, Yifei, Ren, Lijie, Lu, Qiongyu, Tang, Chaojun, Ruan, Changgeng, Zhang, Yonghong, and Zhu, Li
- Subjects
LOW density lipoproteins ,RECEIVER operating characteristic curves ,BODY mass index ,SERUM ,BLOOD sugar ,STROKE - Abstract
Semaphorin 7A (Sema7A), a neural guidance cue, was recently identified to regulate atherosclerosis in mice. However, the clinical relevance of Sema7A with atherosclerotic diseases remains unknown. The aim of this study was to investigate the association between serum Sema7A and the risk of acute atherothrombotic stroke (AAS). We measured serum concentrations of Sema7A in 105 newly onset AAS cases and 105 age‐ and sex‐matched controls, showing that median Sema7A level in AAS cases was over three times of that in controls (5.86 vs 1.66 ng/mL). Adjusted for hypertension, body mass index, fasting blood glucose, total cholesterol, triglyceride, high‐density lipoprotein (HDL)‐cholesterol, low‐density lipoprotein (LDL)‐cholesterol, current smoking and alcohol consumption, multivariate logistic regression showed that higher Sema7A was independently associated with the odds of AAS (OR = 6.40, 95% CI: 2.88‐14.25). Each 1‐standard deviation increase in Sema7A was associated with a threefold higher odds of AAS (OR = 3.42, 95% CI: 1.84‐6.35). Importantly, adding Sema7A to a multivariate logistic model containing conventional cardiovascular risk factors improved the area under receiver operating characteristic curves from 0.831 to 0.891 for the association with AAS. In conclusion, elevated serum Sema7A is independently associated with the risk of AAS, suggesting that it may play a potential role in AAS. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Increased Levels of Plasma Soluble Sema4D in Patients with Heart Failure
- Author
-
Lu, Qiongyu, Dong, Ningzheng, Wang, Qi, Yi, Wenxiu, Wang, Yuxin, Zhang, Shengjie, Gu, Haibo, Zhao, Xin, Tang, Xiaorong, Jin, Boquan, Wu, Qingyu, Brass, Lawrence F., and Zhu, Li
- Subjects
- *
HEART failure , *SEMAPHORINS , *GLYCOPROTEINS , *MEMBRANE proteins , *CD8 antigen , *GENE expression , *TYPE 1 diabetes - Abstract
Semaphorin 4D (Sema4D/CD100) is a 150-kDa transmembrane glycoprotein expressed by platelets and T-cells. When these cells are activated, Sema4D is cleaved proteolytically, generating a biologically active 120-kDa fragment (soluble Sema4D) capable of targeting receptors on platelets, B-cells, endothelial cells and tumor cells. However, its plasma levels and significance in heart failure (HF) have not been reported. In this study, we established an ELISA and detected soluble Sema4D in human plasma. In healthy controls, plasma Sema4D levels were higher in men than women (5.15±3.30 ng/mL, n = 63, vs. 4.19±2.39 ng/mL, n = 63, P<0.05). In HF patients, plasma Sema4D levels were significantly higher than those in healthy controls (8.94±5.89 ng/mL, n = 157 vs. 4.67±2.99 ng/mL, n = 126, P<0.0001) with the highest levels being in HF patients with diabetes mellitus (DM) (10.45±5.76 ng/mL, n = 40). We also found that there was a higher percentage of Sema4Dhigh CD3+ (P<0.01), CD4+ (P<0.001), and CD8+ (P<0.01) T-cells in samples from HF patients, but no changes in Sema4D expression levels in B cells and platelets. Therefore, our investigation shows that plasma Sema4D levels are increased in HF patients, especially in those who also have diabetes. There was an accompanying increase in the Sema4Dhigh population of T-cells, suggesting a potential role of these T-cells in heart failure. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. A Humanin Analog Attenuates Platelet Responses to Vascular Injury
- Author
-
Ren, Lijie, Li, Qiang, Zeng, Zhao, Mou, Peipei, Liu, Xiaohui, Tang, Xiaorong, Lu, Qiongyu, Xu, Xingshun, and Zhu, Li
- Published
- 2011
- Full Text
- View/download PDF
11. Correction: Increased Levels of Plasma Soluble Sema4D in Patients with Heart Failure.
- Author
-
Lu, Qiongyu, Dong, Ningzheng, Wang, Qi, Yi, Wenxiu, Wang, Yuxin, Zhang, Shengjie, Gu, Haibo, Zhao, Xin, Tang, Xiaorong, Jin, Boquan, Wu, Qingyu, Brass, Lawrence F., and Zhu, Li
- Subjects
- *
HEART failure patients - Published
- 2019
- Full Text
- View/download PDF
12. The Role of Semaphorins in Metabolic Disorders.
- Author
-
Lu, Qiongyu and Zhu, Li
- Subjects
- *
SEMAPHORINS , *METABOLIC disorders , *DIABETIC nephropathies , *DIABETIC retinopathy , *DIABETIC neuropathies , *WOUND healing , *TUMOR growth - Abstract
Semaphorins are a family originally identified as axonal guidance molecules. They are also involved in tumor growth, angiogenesis, immune regulation, as well as other biological and pathological processes. Recent studies have shown that semaphorins play a role in metabolic diseases including obesity, adipose inflammation, and diabetic complications, including diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, diabetic wound healing, and diabetic osteoporosis. Evidence provides mechanistic insights regarding the role of semaphorins in metabolic diseases by regulating adipogenesis, hypothalamic melanocortin circuit, immune responses, and angiogenesis. In this review, we summarize recent progress regarding the role of semaphorins in obesity, adipose inflammation, and diabetic complications. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Single-cell transcriptional profiling of human carotid plaques reveals a subpopulation of endothelial cells associated with stroke incidences.
- Author
-
Li F, Du Y, Hong L, Liu Z, Yan K, Liu C, Zhu Z, Lu Q, Tang C, and Zhu L
- Subjects
- Carotid Arteries pathology, Endothelial Cells, Humans, Incidence, Plaque, Atherosclerotic genetics, Plaque, Atherosclerotic pathology, Stroke pathology
- Abstract
The differences in plaque histology between symptomatic and asymptomatic patients have been widely accepted. Whether there is a heterogeneity of cells between symptomatic and asymptomatic plaques remains largely unclear. To reveal the potential heterogeneity within different plaques, which may contribute to different stroke incidences, we obtained the scRNA-seq data from symptomatic and asymptomatic patients and identified eight cell types present in plaques. Further analysis of endothelial cells (ECs) revealed three distinct EC subpopulations appeared to be endowed with specific biological functions such as antigen processing and presentation, cell adhesion, and smooth muscle cell proliferation. Of note, the differentially expressed genes of the EC 2 subpopulation showed that the genes involved in cell adhesion were up-regulated in asymptomatic plaques compared to symptomatic plaques. Integrating the data of intraplaque haemorrhage and plaque stability, the 5th top-enriched biological process was cell adhesion in the stable or non-haemorrhaged plaques compared to unstable plaques or haemorrhaged plaques. Among these cell adhesion-related genes, the intersection gene AOC3 may play a vital role in plaque haemorrhage and plaque stability. Targeting cell adhesion and the specialized genes may provide potential new therapeutic directions to prevent asymptomatic patients from stroke., (© 2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
14. Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia.
- Author
-
Xu X, Lu Q, Wang Z, Cai P, Zeng Z, Zhang L, Wang M, Ma L, Ruan C, and Chen S
- Subjects
- Adult, Biopsy, Bone Marrow pathology, Casein Kinase II genetics, Eosinophilia blood, Eosinophilia diagnosis, Eosinophilia drug therapy, Gene Rearrangement, Humans, Imatinib Mesylate therapeutic use, Male, Myeloproliferative Disorders blood, Myeloproliferative Disorders diagnosis, Myeloproliferative Disorders drug therapy, Treatment Outcome, Eosinophilia genetics, Myeloproliferative Disorders genetics, Oncogene Proteins, Fusion genetics, Receptor, Platelet-Derived Growth Factor beta genetics
- Abstract
Platelet-derived growth factor receptor beta (PDGFRB) rearrangements play an important role in the pathogenesis of eosinophilia-associated myeloid/lymphoid neoplasms. Up to now, more than 70 PDGFRB fusions have been identified. Here, a novel PDGFRB fusion gene CSNK2A1-PDGFRB has been identified in myeloproliferative neoplasm (MPN) with eosinophilia by RNA-sequencing, which has been verified by reverse transcription polymerase chain reaction and Sanger sequencing. The new PDGFRB fusion partner gene CSNK2A1 encoded one of the two catalytic subunit of casein kinase II (CK2). To our knowledge, this is the first report on the involvement of CSNK2A1 in fusion genes, especially fusion with another kinase PDGFRB in MPN. In addition, the CSNK2A1-PDGFRB fusion retained the entire kinase domain of PDGFRB and response to imatinib at low concentration. The patient with CSNK2A1-PDGFRB was sensitive to imatinib treatment and acquired sustained complete remission.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.